Media headlines about Healthequity (NASDAQ:HQY) have been trending somewhat positive this week, according to Accern. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Healthequity earned a news impact score of 0.24 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.1185596512092 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the headlines that may have effected Accern Sentiment’s scoring:
Shares of Healthequity (HQY) traded up $1.36 during midday trading on Monday, reaching $52.65. The company’s stock had a trading volume of 973,460 shares, compared to its average volume of 475,368. Healthequity has a 12 month low of $37.62 and a 12 month high of $55.31. The stock has a market cap of $3,190.00, a P/E ratio of 71.15, a price-to-earnings-growth ratio of 1.96 and a beta of 1.70.
Healthequity (NASDAQ:HQY) last issued its quarterly earnings results on Tuesday, December 5th. The company reported $0.17 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.13 by $0.04. The company had revenue of $56.80 million for the quarter, compared to the consensus estimate of $55.27 million. Healthequity had a return on equity of 14.47% and a net margin of 21.08%. Healthequity’s revenue was up 31.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.10 EPS. research analysts anticipate that Healthequity will post 0.73 EPS for the current fiscal year.
A number of research firms have weighed in on HQY. BidaskClub raised Healthequity from a “sell” rating to a “hold” rating in a research note on Tuesday, November 7th. Zacks Investment Research raised Healthequity from a “hold” rating to a “buy” rating and set a $57.00 price objective on the stock in a research note on Saturday. JPMorgan Chase & Co. reduced their target price on Healthequity from $52.00 to $51.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 24th. Cantor Fitzgerald lifted their target price on Healthequity from $56.00 to $60.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. Finally, Robert W. Baird lifted their target price on Healthequity from $48.00 to $49.00 and gave the company a “neutral” rating in a research report on Wednesday, February 7th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $56.67.
In other Healthequity news, insider Jon Kessler sold 40,000 shares of the company’s stock in a transaction that occurred on Thursday, January 25th. The stock was sold at an average price of $49.47, for a total transaction of $1,978,800.00. Following the completion of the sale, the insider now directly owns 485,000 shares of the company’s stock, valued at approximately $23,992,950. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Berkley Capital, Llc sold 23,479 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $51.08, for a total value of $1,199,307.32. The disclosure for this sale can be found here. Over the last three months, insiders sold 371,426 shares of company stock valued at $18,749,703. Insiders own 19.00% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Healthequity (NASDAQ:HQY) Share Price” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/12/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-healthequity-hqy-stock-price.html.
Healthequity Company Profile
HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.
Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.